65. 原発性免疫不全症候群 Primary immunodeficiency Clinical trials / Disease details

臨床試験数 : 500 / 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217

27 trials found

diseases per page:

Showing 1 to 10 of 27 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05463133 (ClinicalTrials.gov)	July 8, 2022	15/7/2022	Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an A ...	Phase I/II Study Using Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous ...	Chronic Granulomatous Disease	Drug: Sirolimus;Drug: Cyclophosphamide;Drug: Alemtuzumab;Drug: Busulfan;Biological: Pheripheral bloo ...	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Recruiting	4 Years	65 Years	All	50	Phase 1/Phase 2	United States
2	NCT04339777 (ClinicalTrials.gov)	September 22, 2020	8/4/2020	Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity	A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantfor Patients With Inborn Errors of ...	Lymphoproliferative Disorders;Autoimmune Lymphoproliferative;Immune System Diseases;Common Variable ...	Drug: Busulfan test dose;Drug: Fludarabine;Drug: Busulfan;Drug: Alemtuzumab;Radiation: Total body Irr ...	National Cancer Institute (NCI)	NULL	Recruiting	4 Years	69 Years	All	66	Phase 2	United States
3	NCT04400045 (ClinicalTrials.gov)	May 22, 2020	19/5/2020	Low Dose Treosulfan Based Conditioning Regimen in HSCT for Nijmegen Breakage Syndrome	Clinical Open-label Phase 2 Study of Low Dose Treosulfan Based Conditioning Regimen Efficacy in Hema ...	Nijmegen Breakage Syndrome	Drug: Treosulfan	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	NULL	Recruiting	3 Months	21 Years	All	10	Phase 2	Russian Federation
4	NCT03879876 (ClinicalTrials.gov)	May 13, 2020	15/3/2019	Safety and Efficacy Study of Human T Lymphoid Progenitor (HTLP) Injection After Partially HLA Compat ...	A Phase I/II Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Inje ...	Pediatric Patients;Any Type of Severe Combined Immunodeficiency (SCID);Partial HLA Incompatible Allo ...	Drug: Human T Lymphoid Progenitor (HTLP) injection	Assistance Publique - Hôpitaux de Paris	NULL	Recruiting	2 Years	18 Years	All	12	Phase 1/Phase 2	France
5	EUCTR2018-001029-14-FR (EUCTR)	25/10/2018	02/07/2018	HTLP	A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) inje ...	SCID pediatric patients (n=12 for analysis) requiring an HLA partially compatible allogeneic HSCT. M ...	Product Name: HTLP Product Code: HTLP	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12	Phase 1;Phase 2	France
6	NCT02162420 (ClinicalTrials.gov)	January 10, 2015	10/6/2014	Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia	Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia	Dyskeratosis Congenita;Aplastic Anemia	Drug: Alemtuzumab;Drug: Fludarabine;Drug: Cyclophosphamide;Radiation: Total Body Irradiation;Biologi ...	Masonic Cancer Center, University of Minnesota	NULL	Recruiting	0 Years	70 Years	All	50	N/A	United States
7	NCT02179359 (ClinicalTrials.gov)	September 2, 2014	27/6/2014	Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies	MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplantfor Patients With High Risk Hemoglobinopath ...	Sickle Cell Disease;Transfusion Dependent Alpha- or Beta- Thalassemia;Diamond Blackfan Anemia;Paroxy ...	Drug: Reduced Toxicity Ablative Regimen;Drug: Reduced Intensity Preparative Regimen;Drug: Myeloablat ...	Masonic Cancer Center, University of Minnesota	NULL	Recruiting	N/A	55 Years	All	25	N/A	United States
8	NCT02177760 (ClinicalTrials.gov)	July 2014	19/6/2014	Sirolimus Prophylaxis for aGVHD in TME SCID	Sirolimus in Prevention of aGVHD in Maternally Engrafted (TME) Severe Combined Immunodeficiency (SCI ...	Severe Combined Immunodeficiency;Transplacental Maternal Engraftment;Stem Cell Transplant	Drug: Sirolimus	University of California, San Francisco	NULL	Withdrawn	N/A	1 Year	Both	0	Phase 2	United States
9	NCT01917708 (ClinicalTrials.gov)	January 2014	24/7/2013	Bone Marrow Transplant With Abatacept for Non-Malignant Diseases	Abatacept for Post-Transplant Immune Suppression in Children and Adolescents Receiving Allogeneic He ...	Hurler Syndrome;Fanconi Anemia;Glanzmann Thrombasthenia;Wiskott-Aldrich Syndrome;Chronic Granulomato ...	Drug: Abatacept	Emory University	NULL	Completed	N/A	21 Years	All	10	Phase 1	United States
10	NCT01998633 (ClinicalTrials.gov)	December 2013	29/10/2013	Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies ...	Reduced-Intensity Conditioning for Children and Adults With Hemophagocytic Syndromes or Selected Pri ...	Hemophagocytic Lymphohistiocytosis;Chronic Active Epstein-Barr Virus Infection;Chronic Granulomatous ...	Biological: Hematopoietic Stem Cell Transplant	Medical College of Wisconsin	National Heart, Lung, and Blood Institute (NHLBI);Blood and Marrow Transplant Clinical Trials Networ ...	Completed	4 Months	45 Years	All	47	Phase 2	United States;Canada

First Previous1 2 3Next Last